| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Arcutis Biotherapeutics, Inc.
13D/A
ARQT · 03969K108
|
7.5% |
8/20/2025
Event 8/18/2025
|
||||
| Frazier Life Sciences VIII, L.P. | 7.3% | |||||
| FHM Life Sciences VIII, L.P. | 7.4% | |||||
| FHM Life Sciences VIII, L.L.C. | 7.4% | |||||
| Frazier Life Sciences X, L.P. | 0% | |||||
| FHMLS X, L.P. | 0% | |||||
| FHMLS X, L.L.C. | 0% | |||||
| Frazier Life Sciences Public Fund, L.P. | 0.6% | |||||
| FHMLSP, L.P. | 0.6% | |||||
| FHMLSP, L.L.C. | 0.6% | |||||
| Frazier Life Sciences Public Overage Fund, L.P. | 0.2% | |||||
| FHMLSP Overage, L.P. | 0.2% | |||||
| FHMLSP Overage, L.L.C. | 0.2% | |||||
| Frazier Life Sciences XI, L.P. | 0.1% | |||||
| FHMLS XI, L.P. | 0.1% | |||||
| FHMLS XI, L.L.C. | 0.1% | |||||
| Frazier Life Sciences XII, L.P. | 0.1% | |||||
| FHMLS XII, L.P. | 0.1% | |||||
| FHMLS XII, L.L.C. | 0.1% | |||||
| James N. Topper | 7.4% | |||||
| Patrick J. Heron | 7.5% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.